Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder

Psychiatry Research

Volumn 253, Issue , 2017, Pages 174-181

  Vittengl, Jeffrey R ^a   Anna Clark, Lee ^b   Thase, Michael E ^c   Jarrett, Robin B ^d  

^a TRUMAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cognitive therapy; Fluoxetine; Major depressive disorder; Personalized advantage index; Personalized medicine; Recurrence; Relapse

Indexed keywords

FLUOXETINE; PLACEBO; ANTIDEPRESSANT AGENT;

ADULT; AGE; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PERSONALITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; RISK REDUCTION; SURVIVAL ANALYSIS; SYMPTOM; MIDDLE AGED; PATIENT SELECTION; PROCEDURES; PSYCHOLOGY; RISK FACTOR;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RECURRENCE; RISK FACTORS;

EID: 85016819305     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2017.03.032     Document Type: Article

References (45)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. fourth ed, 2000, American Psychiatric Association, Washington, DC.
2. Beck, A.T., Rush, A.J., Shaw, B.F., Emery, G., Cognitive Therapy of Depression. 1979, Guilford Press, New York.
3. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., An inventory for measuring depression. Arch. Gen. Psychiatry 4 (1961), 561–571.
4. Biesheuvel-Leliefeld, K.M., Kok, G.D., Bockting, C.H., Cuijpers, P., Hollon, S.D., van Marwijk, H.J., Smit, F., Effectiveness of psychological interventions in preventing recurrence of depressive disorder: meta-analysis and Meta-regression. J. Affect. Disord. 174 (2015), 400–410.
5. Blackburn, I.M., Eunson, K.M., Bishop, S., A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J. Affect. Disord. 10 (1986), 67–75.
6. Blackburn, I., Moore, R.G., Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br. J. Psychiatry 171 (1997), 328–334.
7. Chouinard, G., Chouinard, V., New classification of selective serotonin reuptake inhibitor withdrawal. Psychother. Psychosom. 84 (2015), 63–71.
8. Clark, L.A., Simms, L.J., Wu, K.D., Casillas, A., 2014. Schedule for Nonadapative and Adaptive Personality—2nd Edition (SNAP-2): Manual for Administration, Scoring, and Interpretation. University of Notre Dame, Notre Dame, IN.
9. Cuijpers, P., Berking, M., Andersson, G., Quigley, L., Kleiboer, A., Dobson, K.S., A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can. J. Psychiatry 58 (2013), 376–385.
10. Cuijpers, P., Hollon, S.D., van Straten, A., Bockting, C., Berking, M., Andersson, G., Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open, 3(4), 2013, 10.1136/bmjopen-2012-002542.
11. Cuijpers, P., Weitz, E., Twisk, J., Kuehner, C., Cristea, I., David, D., DeRubeis, R.J., Dimidjian, S., Dunlop, B.W., Faramarzi, M., Hegerl, U., Jarrett, R.B., Kennedy, S.H., Kheirkhah, F., Mergl, R., Miranda, J., Mohr, D.C., Segal, Z.V., Siddique, J., Simons, A.D., Vittengl, J.R., Hollon, S.D., Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an ‘individual patient data’ meta‐analysis. Depress. Anxiety 31 (2014), 941–951.
12. DeRubeis, R.J., Cohen, Z.D., Forand, N.R., Fournier, J.C., Gelfand, L.A., Lorenzo-Luaces, L., The personalized advantage index: Translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One, 9(1), 2014, e83875.
13. Fawcett, J., Epstein, P., Fiester, S., Elkin, I., Autry, J., Clinical management–imipramine/placebo administration manual. NIMH treatment of depression collaborative Research program. Psychopharmacol. Bull. 23 (1987), 309–324.
14. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B., 1996. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York State Psychiatric Institute, Biometrics Research Department, New York.
15. Guidi, J., Tomba, E., Fava, G.A., The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am. J. Psychiatry 173 (2016), 128–137.
16. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–61.
17. Hansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., Lohr, K., Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr. Serv. 59 (2008), 1121–1130.
18. Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W.A., Beekman, A.F., Recurrence of major depressive disorder and its predictors in the general population: Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol. Med. 43 (2013), 39–48.
19. Huibers, M.H., Cohen, Z.D., Lemmens, L.M., Arntz, A., Peeters, F.L., Cuijpers, P., DeRubeis, R.J., Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed Individuals using the personalized advantage index approach. Plos One, 10(11), 2015, e0140771.
20. Jarrett, R.B., Cognitive therapy for recurrent unipolar major depressive disorder: the continuation/maintenance phase. Unpubl. Treat. Man., 1989.
21. Jarrett, R.B., Kraft, D., Doyle, J., Foster, B.M., Eaves, G.G., Silver, P.C., Preventing recurrent depression using cognitive therapy with and without a continuation phase. Arch. Gen. Psychiatry 58 (2001), 381–388.
22. Jarrett, R.B., Kraft, D., Schaffer, M., Witt-Browder, A., Risser, R., Atkins, D.H., Doyle, J., Reducing relapse in depressed outpatients with atypical features: a pilot study. Psychother. Psychosom. 69 (2000), 232–239.
23. Jarrett, R.B., Minhajuddin, A., Gershenfeld, H., Friedman, E.S., Thase, M.E., Preventing depressive relapse and recurrence in higher risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry 70 (2013), 1152–1160.
24. Jarrett, R.B., Vittengl, J.R., Clark, L.A., Preventing recurrent depression. Whisman, M.A., (eds.) Adapting Cognitive Therapy for Depression: Managing Complexity and Comorbidity, 2008, Guilford Press, New York, 132–156.
25. Jarrett, R.B., Vittengl, J.R., Clark, L.A., Thase, M.E., Skills of cognitive therapy (SoCT): a new measure of patients' comprehension and use. Psychol. Assess. 23 (2011), 578–586.
26. Jarrett, R.B., Thase, M.E., Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up. Contemp. Clin. Trials 31 (2010), 355–377.
27. Kazdin, A.E., Understanding how and why psychotherapy leads to change. Psychother. Res 19 (2009), 418–428.
28. Keller, M.B., Lavori, P.W., Friedman, B., Nielsen, E., Endicott, J., McDonald-Scott, P., Andreasen, N.C., The longitudinal interval follow-up evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch. Gen. Psychiatry 44 (1987), 540–548.
29. Kessler, R.C., de Jonge, P., Shahly, V., van Loo, H.M., Wang, P.S., Wilcox, M.A., Epidemiology of depression. Gotlib, I.H., Hammen, C.L., Gotlib, I.H., Hammen, C.L., (eds.) Handbook of Depression, third ed, 2014, Guilford, New York, 7–24.
30. Kraemer, H., Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Stat. Med. 32 (2013), 1964–1973.
31. Kuyken, W., Byford, S., Taylor, R.S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., Mullan, E., Teasdale, J.D., Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J. Consult. Clin. Psychol. 76 (2008), 966–978.
32. Kuyken, W., Hayes, R., Barrett, B., Byng, R., Dalgleish, T., Kessler, D., Lewis, G., Watkins, E., Brejcha, C., Cardy, J., Causley, A., Cowderoy, S., Evans, A., Gradinger, F., Kaur, S., Lanham, P., Morant, N., Richards, J., Shah, P., Sutton, H., Vicary, R., Weaver, A., Wilks, J., Williams, M., Taylor, R.S., Byford, S., Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (prevent): a randomised controlled trial. Lancet 386 (2015), 63–73.
33. Ma, Y., Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis. Mol. Psychiatry 20 (2015), 311–319.
34. Patten, S.B., Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry, 9, 2009, 19.
35. Rush, A.J., Gullion, C.M., Basco, M.R., Jarrett, R.B., Trivedi, M.H., The inventory of depressive symptomatology (ids): Psychometric properties. Psychol. Med. 26 (1996), 477–486.
36. Segal, Z.V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., Levitan, R.D., Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch. Gen. Psychiatry 67 (2010), 1256–1264.
37. Simon, G.E., Perlis, R.H., Personalized medicine for depression: can we match patients with treatments?. Am. J. Psychiatry 167 (2010), 1445–1455.
38. Smagula, S.F., Wallace, M.L., Anderson, S.J., Karp, J.F., Lenze, E.J., Mulsant, B.H., Butters, M.A., Blumberger, D.M., Diniz, B.S., Lotrich, F.E., Dew, M.A., Reynolds, C.I., Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. J. Psychiatr. Res. 8 (2016), 1112–1118.
39. Tyrer, P., Tyrer, H., Guo, B., The general neurotic syndrome: a re-evaluation. Psychother. Psychosom. 85 (2016), 193–197.
40. Vittengl, J.R., Clark, L.A., Dunn, T.W., Jarrett, R.B., Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J. Consult. Clin. Psychol. 75 (2007), 475–488.
41. Vittengl, J.R., Clark, L.A., Jarrett, R.B., Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression. Behav. Res. Ther. 48 (2010), 449–458.
42. Vittengl, J.R., Clark, L.A., Thase, M.E., Jarrett, R.B., Nomothetic and idiographic symptom change trajectories in acute-phase cognitive therapy for recurrent depression. J. Consult. Clin. Psychol. 81 (2013), 615–626.
43. Vittengl, J.R., Clark, L.A., Thase, M.E., Jarrett, R.B., Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder. Psychotherapy 52 (2015), 268–277.
44. Wallace, M., Frank, E., Kraemer, H., A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 70 (2013), 1241–1247.
45. Young, J., Beck, A.T., Cognitive Therapy Scale: rating Manual. 1980, Center for Cognitive Therapy, Philadelphia, PA.